Currently, only six drugs, including four cholinesterase inhibitors, one N-methyl-d-aspartate (NMDA) receptor antagonist, and one monoclonal antibody against A-beta, have been approved by the FDA for the treatment of AD (Xu et al., 2016; Zhang J. et al., 2020). The gene discussed is APP; the disease is Alzheimer disease.